Formulary Search Results for: CALCIUM AND VITAMIN D
If the searched medicine is not listed in the NHSGGC Formulary, please check if the relevant therapeutic chapter is now available on the West of Scotland Formulary — visit formulary.nhs.scot/west.
9.1.8 Drugs for other blood disorders - View Category
Total Formulary
ETRANACOGENE DEZAPARVOVEC (HEMGENIX)
Restrictions:
Restricted to specialist use for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.
9.5.2.2 Phosphate-binding agents - View Category
Total Formulary
8.1.5 Other antineoplastic drugs - View Category
Total Formulary
TRASTUZUMAB DERUXTECAN (Enhertu) (infusion)
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following indications:
Breast cancer
- As monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received one or more prior anti-HER2-based regimens.
- As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Prescribing Notes:
Trastuzumab deruxtecan is currently non-formulary for the following indications:
- Gastric or gastroesophageal junction adenocarcinoma: As monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
- Non-small cell lung cancer: As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
- Breast cancer: Treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultra low breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.
- Treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options.